Global Psychedelic Drugs Market - Industry Trends and Forecast to 2029

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 25
1.1 OBJECTIVES OF THE STUDY 25
1.2 MARKET DEFINITION 25
1.3 OVERVIEW OF GLOBAL PSYCHEDELIC DRUGS MARKET 25
1.4 LIMITATIONS 27
1.5 MARKETS COVERED 27
2 MARKET SEGMENTATION 30
2.1 MARKETS COVERED 30
2.2 GEOGRAPHICAL SCOPE 31
2.3 YEARS CONSIDERED FOR THE STUDY 32
2.4 CURRENCY AND PRICING 32
2.5 DBMR TRIPOD DATA VALIDATION MODEL 33
2.6 MULTIVARIATE MODELLING 36
2.7 TYPE LIFELINE CURVE 36
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 37
2.9 DBMR MARKET POSITION GRID 38
2.10 MARKET END USER COVERAGE GRID 39
2.11 VENDOR SHARE ANALYSIS 40
2.12 SECONDARY SOURCES 41
2.13 ASSUMPTIONS 41
3 EXECUTIVE SUMMARY 42
4 PREMIUM INSIGHT 46
4.1 PIPELINE ANALYSIS 48
4.2 PESTEL ANALYSIS 50
4.3 PORTER'S FIVE FORCES MODEL 51
5 REGULATORY FRAMEWORK: GLOBAL PSYCHEDELIC DRUGS MARKET 52
5.1 REGULATORY SCENARIO IN THE U.S. 52
5.2 REGULATORY SCENARIO IN THE U.K. 53
5.3 REGULATORY SCENARIO IN INDIA 54
5.4 REGULATORY SCENARIO IN UAE 54
5.5 REGULATORY SCENARIO IN AFRICA 55
5.6 REGULATORY SCENARIO IN BRAZIL 55

6 MARKET OVERVIEW 57
6.1 DRIVERS 59
6.1.1 GROWING ACCEPTANCE OF PSYCHEDELIC DRUGS TO TREAT DEPRESSION 59
6.1.2 INCREASING PREVALENCE OF DEPRESSION AND MENTAL DISORDERS 61
6.1.3 RISING AWARENESS TOWARD MENTAL HEALTH 64
6.1.4 ONGOING CLINICAL TRIALS 65
6.1.5 RISE IN PRODUCT APPROVALS 66
6.2 RESTRAINTS 66
6.2.1 STRINGENT REGULATIONS FOR PSYCHEDELIC DRUGS 66
6.2.2 HIGH COST OF PSYCHEDELIC DRUGS 69
6.2.3 PATENT EXPIRY OF PSYCHEDELIC DRUGS 70
6.3 OPPORTUNITIES 71
6.3.1 INCREASING R&D ACTIVITIES IN PSYCHEDELIC DRUGS 71
6.3.2 BREAKTHROUGH THERAPY DESIGNATION BY REGULATORY AUTHORITY 73
6.3.3 UPCOMING REHABILITATION CENTERS 74
6.3.4 AVAILABILITY OF CERTIFIED HEALTHCARE PROFESSIONALS 75
6.4 CHALLENGES 75
6.4.1 SIDE EFFECTS ASSOCIATED WITH PSYCHEDELIC DRUGS 75
6.4.2 RISE IN ILLEGAL ALTERNATIVES 77
6.4.3 AVAILABILITY OF OTHER TREATMENT OPTIONS 77
7 COVID-19 IMPACT ON THE GLOBAL PSYCHEDELIC DRUGS MARKET 78
7.1 IMPACT ON PRICE 78
7.2 IMPACT ON DEMAND 78
7.3 IMPACT ON SUPPLY CHAIN 79
7.4 STRATEGIC DECISIONS FOR MANUFACTURERS 79
7.5 CONCLUSION 80
8 GLOBAL PSYCHEDELIC DRUGS MARKET, BY TYPE 81
8.1 OVERVIEW 82
8.2 EMPATHOGENS 85
8.3 DISSOCIATIVES 86
8.4 OTHERS 87
9 GLOBAL PSYCHEDELIC DRUGS MARKET, BY SOURCE 88
9.1 OVERVIEW 89
9.2 SYNTHETIC 92
9.3 NATURAL 93

10 GLOBAL PSYCHEDELIC DRUGS MARKET, BY DRUGS 94
10.1 OVERVIEW 95
10.2 GAMMA-HYDROXYBUTYRIC ACID 98
10.3 KETAMINE 99
10.4 PSILOCYBIN 100
10.5 OTHERS 101
11 GLOBAL PSYCHEDELIC DRUGS MARKET, BY APPLICATION 102
11.1 OVERVIEW 103
11.2 NARCOLEPSY 106
11.3 TREATMENT RESISTANT DEPRESSION 107
11.4 MAJOR DEPRESSIVE DISORDER 108
11.5 OPIATE ADDICTION 109
11.6 POST-TRAUMATIC STRESS DISORDER 110
11.7 OTHERS 111
12 GLOBAL PSYCHEDELIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION 112
12.1 OVERVIEW 113
12.2 ORAL 116
12.3 INHALATION 117
12.4 INJECTABLE 118
13 GLOBAL PSYCHEDELIC DRUGS MARKET, BY END USER 119
13.1 OVERVIEW 120
13.2 HOSPITALS 123
13.3 SPECIALTY CLINICS 124
13.4 HOMECARE 125
13.5 OTHERS 126
14 GLOBAL PSYCHEDELIC DRUGS MARKET, BY DISTRIBUTION CHANNEL 127
14.1 OVERVIEW 128
14.2 HOSPITALS PHARMACY 131
14.3 RETAIL PHARMACY 132
14.4 ONLINE PHARMACY 133
15 GLOBAL PSYCHEDELIC DRUGS MARKET, BY REGION 134
15.1 OVERVIEW 135
15.2 NORTH AMERICA 141
15.2.1 U.S. 148
15.2.2 CANADA 150
15.2.3 MEXICO 152
15.3 EUROPE 154
15.3.1 GERMANY 163
15.3.2 U.K. 165
15.3.3 FRANCE 168
15.3.4 ITALY 170
15.3.5 SPAIN 173
15.3.6 RUSSIA 175
15.3.7 POLAND 178
15.3.8 SWITZERLAND 181
15.3.9 NETHERLANDS 184
15.3.10 HUNGARY 187
15.3.11 AUSTRIA 190
15.3.12 NORWAY 193
15.3.13 IRELAND 196
15.3.14 BELGIUM 199
15.3.15 LITHUANIA 202
15.3.16 REST OF EUROPE 205
15.4 ASIA-PACIFIC 206
15.4.1 INDIA 214
15.4.2 AUSTRALIA 217
15.4.3 SOUTH KOREA 220
15.4.4 SINGAPORE 223
15.4.5 MALAYSIA 226
15.5 MIDDLE EAST & AFRICA 229
15.5.1 SAUDI ARABIA 237
15.5.2 ISRAEL 240
15.5.3 EGYPT 243
15.5.4 UAE 246
15.5.5 SOUTH AFRICA 248
15.6 SOUTH AMERICA 251
15.6.1 BRAZIL 259
15.6.2 ARGENTINA 262
15.6.3 REST OF SOUTH AMERICA 265
16 GLOBAL PSYCHEDELIC DRUGS MARKET: COMPANY LANDSCAPE 266
16.1 COMPANY SHARE ANALYSIS: GLOBAL 266
16.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 267
16.3 COMPANY SHARE ANALYSIS: EUROPE 268
16.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 269
17 SWOT ANALYSIS 270
18 COMPANY PROFILE 271
18.1 JAZZ PHARMACEUTICALS, INC. 271
18.1.1 COMPANY SNAPSHOT 271
18.1.2 REVENUE ANALYSIS 272
18.1.3 COMPANY SHARE ANALYSIS 272
18.1.4 PRODUCT PORTFOLIO 272
18.1.5 RECENT DEVELOPMENTS 273
18.2 PFIZER INC. 274
18.2.1 COMPANY SNAPSHOT 274
18.2.2 REVENUE ANALYSIS 274
18.2.3 COMPANY SHARE ANALYSIS 275
18.2.4 PRODUCT PORTFOLIO 275
18.2.5 RECENT DEVELOPMENTS 275
18.3 F. HOFFMANN- LA ROCHE LTD 276
18.3.1 COMPANY SNAPSHOT 276
18.3.2 REVENUE ANALYSIS 276
18.3.3 COMPANY SHARE ANALYSIS 277
18.3.4 PRODUCT PORTFOLIO 277
18.3.5 RECENT DEVELOPMENT 277
18.4 JANSSEN GLOBAL SERVICES, LLC (A SUBSIDIARY OF JOHNSON & JOHNSON SERVICES, INC.) 278
18.4.1 COMPANY SNAPSHOT 278
18.4.2 COMPANY SHARE ANALYSIS 278
18.4.3 PRODUCT PORTFOLIO 279
18.4.4 RECENT DEVELOPMENT 279
18.5 AVADEL 280
18.5.1 COMPANY SNAPSHOT 280
18.5.2 PRODUCT PORTFOLIO 280
18.5.3 RECENT DEVELOPMENT 280
18.6 CELON PHARMA SA 281
18.6.1 COMPANY SNAPSHOT 281
18.6.2 PRODUCT PORTFOLIO 281
18.6.3 RECENT DEVELOPMENT 281
18.7 COMPASS 282
18.7.1 COMPANY SNAPSHOT 282
18.7.2 PRODUCT PORTFOLIO 282
18.7.3 RECENT DEVELOPMENTS 282

18.8 CYBIN CORP. 283
18.8.1 COMPANY SNAPSHOT 283
18.8.2 PRODUCT PORTFOLIO 283
18.8.3 RECENT DEVELOPMENTS 283
18.9 ENTHEON BIOMEDICAL CORP 284
18.9.1 COMPANY SNAPSHOT 284
18.9.2 PRODUCT PORTFOLIO 284
18.9.3 RECENT DEVELOPMENT 284
18.10 GH RESEARCH 285
18.10.1 COMPANY SNAPSHOT 285
18.10.2 PRODUCT PORTFOLIO 285
18.10.3 RECENT DEVELOPMENT 285
18.11 HIKMA PHARMACEUTICALS PLC 286
18.11.1 COMPANY SNAPSHOT 286
18.11.2 REVENUE ANALYSIS 286
18.11.3 PRODUCT PORTFOLIO 287
18.11.4 RECENT DEVELOPMENTS 287
18.12 NRX PHARMACEUTICALS, INC. 288
18.12.1 COMPANY SNAPSHOT 288
18.12.2 PRODUCT PORTFOLIO 288
18.12.3 RECENT DEVELOPMENT 288
18.13 PHARMATHER HOLDINGS LTD. 289
18.13.1 COMPANY SNAPSHOT 289
18.13.2 PRODUCT PORTFOLIO 289
18.13.3 RECENT DEVELOPMENT 289
18.14 VERRIAN 290
18.14.1 COMPANY SNAPSHOT 290
18.14.2 PRODUCT PORTFOLIO 290
18.14.3 RECENT DEVELOPMENT 290
18.15 USONAINSTITUTE.ORG 291
18.15.1 COMPANY SNAPSHOT 291
18.15.2 PRODUCT PORTFOLIO 291
18.15.3 RECENT DEVELOPMENT 291
19 QUESTIONNAIRE 292
20 RELATED REPORTS 296